RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
国际细胞与基因治疗学会干细胞工程委员会：用于治疗造血干细胞移植后移植物抗宿主病的细胞疗法
英文原题：International Society for Cell & Gene Therapy Stem Cell Engineering Committee: Cellular therapies for the treatment of graft-versus-host-disease after hematopoietic stem cell transplant.
查看英文原题
International Society for Cell & Gene Therapy Stem Cell Engineering Committee: Cellular therapies for the treatment of graft-versus-host-disease after hematopoietic stem cell transplant.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
迄今为止，有许多正在进行的临床试验，有望拓展我们目前对细胞疗法在 GVHD 治疗中作用的认识，以期在不久的将来改善 GVHD 相关结局。
研究思路结论见上方概要
背景
异基因造血干细胞移植是许多恶性和非恶性血液病的治愈性手段。尽管在其预防和治疗方面取得了进展，但与移植物抗宿主病（GVHD）相关的发病率和死亡率仍然存在。目前使用的药物制剂损害潜在同种反应性T细胞活化和增殖的机制，揭示了这些细胞群体有害活性所必需的途径。重要的是，这些相同的途径在因恶性疾病而接受移植的受者中介导移植物抗白血病效应方面可能也很重要。这些知识为间充质基质细胞和调节性T细胞等细胞疗法在预防或治疗GVHD中的潜在作用提供了信息。本文综述了聚焦于GVHD治疗的过继性细胞疗法的现状。
方法
我们在PubMed®中检索了科学文献，并在ClinicalTrials.gov中检索了正在进行的临床试验，关键词为“移植物抗宿主病（GVHD）”、“细胞疗法”、“调节性T细胞（Tregs）”、“间充质基质（干）细胞（MSCs）”、“自然杀伤（NK）细胞”、“髓源性抑制细胞（MDSCs）”和“调节性B细胞（B-regs）”。所有已发表和可获得的临床研究均被纳入。
结果
尽管大多数现有临床数据集中于预防GVHD的细胞疗法，但也有观察性和干预性临床研究探索细胞疗法作为GVHD治疗的安全手段，同时在恶性疾病背景下维持移植物抗白血病效应的潜力。然而，存在多种挑战限制了这些方法在临床场景中的更广泛应用。
展开英文摘要原文
METHODS
We conducted a search for scientific literature in PubMed® and ongoing clinical trials in clinicaltrial.gov with the keywords "Graft-versus-Host Disease (GVHD)," "Cellular Therapies," "Regulatory T cells (Tregs)," "Mesenchymal Stromal (Stem) Cells (MSCs)," "Natural Killer (NK) Cells," "Myeloid-derived suppressor cells (MDSCs)," and "Regulatory B-Cells (B-regs)." All the published and available clinical studies were included.
RESULTS
Although most of the existing clinical data focus on cellular therapies for GVHD prevention, there are observational and interventional clinical studies that explore the potential for cellular therapies to be safe modalities for GVHD treatment while maintaining the graft-versus-leukemia effect in the context of malignant diseases. However, there are multiple challenges that limit the broader use of these approaches in the clinical scenario.
CONCLUSIONS
There are many ongoing clinical trials to date with the promise to expand our actual knowledge on the role of cellular therapies for GVHD treatment in an attempt to improve GVHD-related outcomes in the near future.
论文信息
- 作者
- Garcia-Rosa M、Abraham A、Bertaina A、Bhoopalan SV、Bonfim C、Cohen S、DeZern A、Louis C
- 单位
- Pediatric Hematology-Oncology Fellow, Memorial Sloan Kettering Cancer Center, and Department of Pediatrics, Weill Cornell Medical College of Cornell University, New York, New York, USA. Electronic address: garciam7@mskcc.org.United States
- 文献类型
- 综述
- 期刊
- Cytotherapy2023 Jun
- 原文标识
- PubMed 36941149 · DOI 10.1016/j.jcyt.2023.02.007